Healthy and functional cells from discovery
to manufacturing

We enable transformative therapies with our patent-pending continuous Flowfect® cell engineering platforms. The non-viral Flowfect® technology is a fast, scalable, and gentle process that yields billions of high-quality engineered cells in minutes while maintaining cell health and function.

KYTOPEN enables cell engineering from discovery to manufacturing

Technology

We are transforming cell engineering

The Flowfect® technology combines continuous fluid flow with electric fields for high efficiency delivery of payloads such as mRNA, DNA, and CRISPR Cas9 RNP to primary cells. By carefully synchronizing the pulse delivery with the fluid flow we have eliminated the harmful effects of traditional transfection via static electroporation. Our ex vivo cell engineering platform is compatible with primary cells being developed for immuno-oncology and gene editing applications.

PRESERVED VIABILITY & FUNCTIONALITY

Our platform allows you to safely engineer your cells with minimal impact to their overall health and function. High-quality engineered cell products upfront will ultimate translate into faster cell therapy access for patients.

Kytopen

SCALABLE CELL ENGINEERING

The Flowfect® platform combines proprietary electric fields and continuous fluid flow to engineer cells. We currently process billions of cells in minutes which makes our technology amenable to autologous and allogenic cell therapy applications. Our goal is to enable efficient and cost-effective manufacturing of cell therapies in days versus weeks.

AUTOMATED
HIGH THROUGHPUT
DISCOVERY

We have fully automated cell engineering at the discovery scale. Whether you’re optimizing transfection conditions or discovering the next-generation cell therapy, Flowfect® will accelerate your time to market.

KYTOPEN empowers your cells to flow from theory to therapy

Team

Meet the team

PAULO A. GARCIA, Ph.D.
CEO & Co-Founder

Dr. Paulo A. Garcia co-invented the Flowfect® technology while he was a Research Scientist at MIT. He is currently leading the development and commercialization efforts of the proprietary cell engineering platform for therapeutic and biotechnology applications.

CULLEN R. BUIE, Ph.D.
Co-Founder

Cullen R. Buie, Ph.D. is a Tenured Professor of Mechanical Engineering at MIT and co-inventor of the high-throughput genetic modification technology. He brings expertise in the areas of microfluidics, microfabrication, and experimental fluid mechanics to Kytopen.

BETHANY GRANT, M.S.
Head of Research &
Development

Bethany has focused her career on bringing innovative medical device solutions to market. She led concepts through launch and acquisition, and directed innovation and product development at J&J. She graduated from MIT with a B.S. and M.S. in Aeronautical and Astronautical Engineering.

GREG CRESCENZI, MBA
Chief Commercial Officer

As a seasoned business leader, Greg has spent his career leading teams of sales, marketing, product development and operations professionals in commercializing innovative tools and technologies for advancing the development and manufacturing of Biopharmaceuticals with key industry suppliers including Cytiva/GE Healthcare, BD, Pall and Merck Millipore.

TA-CHUN HANG, Ph.D.
Director of Biology

Ta-Chun Hang has worked in early development through commercial manufacturing for biologics and cell therapies, including supporting regulatory activities as well as heading pilot plant operations. He has combined his breadth of knowledge and expertise to drive innovation and novel approaches in process development. Ta-Chun completed two bachelor’s degrees (Biomedical Engineering, Human Physiology) from the University of Minnesota and a PhD in Biological Engineering from MIT.

JAMES HEMPHILL, Ph.D.
Principal Scientist

James Hemphill, Ph.D. is a genetic engineer focused on building new functionality into human cells for therapeutic application. He received his Ph.D. in chemical biology from the University of Pittsburgh and has experience in platform development for adoptive cell therapy.

MICHAEL ELLIOTT, MBA
Chief Operating Officer

Michael is an accomplished executive in Operations and P&L Management. Managed various manufacturing and operational functions at BD in Diagnostics, Medical Devices, and Biosciences. More recently, led activities for emerging Biotech firms to hyper-scale their business and operational models globally. Michael holds a B.S. in Mechanical Engineering, from BYU, and an MBA, from MIT Sloan.

VERONA OUTERBRIDGE, M.S.
Quality Leader

Verona is an accomplished Quality professional with extensive experience in regulatory compliance and quality management systems supporting pharmaceutical development and market approval. Her background includes regulatory compliance and inspection readiness, business development, laboratory operations, pharmaceutical research, and education. Verona graduated from the University of Massachusetts Boston with a B.S and M.S. in Chemistry.

JOHN ZHAO, M.S.
Process Development Scientist

John Zhao graduated from Cornell with a B.S. in Bioengineering and University of Louisville with a M.S. in Biochemistry. His career has been dedicated to cell therapy in various roles including research, development and manufacturing. His primary focus is innovative process development techniques and applications.

MICHAEL BALADIANG, B.S.
Research Associate

Michael Baladiang, B.S. graduated from the University of Massachusetts Amherst with a degree in biology. He has experience doing work in immunology specifically with efforts in HIV and more recently COVID and focused on optimization and automation of laboratory procedures.

NORMAN WEN
Director of Engineering

Norman has made a career of bringing novel science and technology from research to reality. Previously, he was at Emulate, where he helped lead the buildout of its core technology and business to be a leader in the Organs-on-Chips and advanced in vitro model space. Norman graduated from University of California Berkeley with degrees in Mechanical Engineering B.S. and Materials Science B.S.

ROSS BEIGHLEY, B.S.
Senior Systems Engineer

Ross Beighley, B.S. graduated from Tufts University where he studied Computer Engineering and Biomedical Engineering. His professional experience centers on transitioning benchtop solutions to worldwide markets through automation.

EDUARDO LATOUCHE, M.S.
Engineering Program Manager

Eduardo is a hands-on technical leader and collaborator tackling complex problems. He has experience leading diverse technical teams in the medical technology space. Eduardo studied Engineering Mechanics (M.S.) and Mechanical Engineering (B.S.) at Virginia Tech.

RAMEECH MCCORMACK, M.S.
R&D Engineer

Rameech McCormack, M.S. master’s graduate from the Mechanical Engineering Department at MIT. He is also a co-inventor of the high throughput Flowfect® technology. Rameech leads the effort in product manufacturing, design, and integration.

KYTOPEN enables safer and faster therapeutic development

Publications

The intersection of innovation and opportunity

Kytopen is an MIT spinout with multiple publications in high-impact scientific journals.

KYTOPEN  helps you discover efficiently

Partners

BioCentriq™ is a full service CDMO for cell and gene therapy process development and clinical manufacturing. Their GMP clinical manufacturing facility is in Newark, NJ with a pilot plant in South Brunswick, NJ. They manufacture autologous and allogeneic cell therapies and gene therapies and specialize in viral vector production, cell and viral banking, and upstream and downstream processing.
BioCentriq™ manufactures immunotherapies, including monoclonal antibodies and proteins, and vaccines and they also offer workforce development programs.

Press Release

With Generous Support From

Jobs & Contact

Be part of a dynamic and growing team working at the intersection of engineering, biology, and advanced manufacturing. We have several open positions  and looking forward to receiving your CV/resume at jobs@kytopen.com if you are interested in joining us.

Sr. Research Scientist
GET IN TOUCH





captcha